Britain health regulator revokes conditional marketing authorisation for Novartis sickle cell drug Adakveo
Sickle cell disease is a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death.
Written By : Ruchika Sharma
Medically Reviewed By : Dr. Kamal Kant Kohli
Published On 2024-02-22 05:50 GMT | Update On 2024-03-22 09:54 GMT
Bengaluru: Britain's health regulator said on Wednesday it had revoked a conditional marketing authorisation for Novartis' sickle cell disease drug, Adakveo.
The decision follows the Swiss drugmaker's move to recall a batch of the drug after the Medicines and Healthcare products Regulatory Agency (MHRA) said it no longer considered the treatment's benefits-to-risk balance favourable.
Sickle cell disease is a genetic disorder in which misshapen blood cells cause strokes, organ damage, severe pain and early death.
The European Medicines Agency (EMA) also revoked approval for the drug last year.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd